Physician profile
Gregory Parkhurst
NPI 1689737793
$185,331.52
in general payments reported to CMS, 2019-2025
36 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $2,954 · 2021: $30K · 2022: $115K · 2023: $6,412 · 2024: $8,382 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $7,475 · Consulting Fee: $5,600 · Food and Beverage: $2,154 · Gift: $72.27 · Entertainment: $42.25 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $7,474.85 |
| Consulting Fee | $5,600.00 |
| Food and Beverage | $2,153.78 |
| Gift | $72.27 |
| Entertainment | $42.25 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $106,474.68 | 2022-2023 | |
| Lensar, INC. | $48,400.98 | 2019-2023 | Lensar Laser System |
| Johnson & Johnson Surgical Vision, INC. | $11,443.15 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Amo Phaco Needle |
| Glaukos Corporation | $8,364.22 | 2019-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished) |
| Carl Zeiss Meditec, INC. | $5,694.89 | 2019-2021 | |
| Alcon Vision LLC | $1,193.87 | 2019-2025 | Clareon, Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser |
| Allergan, INC. | $691.73 | 2019-2022 | |
| Biotissue Holdings INC. | $397.02 | 2019-2025 | |
| Rxsight INC | $390.15 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Staar Surgical Company | $325.17 | 2019 | |
| Harrow Eye, LLC | $185.72 | 2024 | Iheezo |
| Quidel Corporation | $176.33 | 2019 | |
| Omeros Corporation | $174.09 | 2019-2021 | |
| Abbvie INC. | $173.34 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $157.28 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $144.09 | 2021-2025 | Cequa |
| Lumibird Medical INC. | $106.08 | 2024 | |
| Rayner Intraocular Lenses Limited | $105.92 | 2022-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Carl Zeiss Meditec USA, INC. | $92.42 | 2021-2025 | Visumax |
| Sight Sciences, INC. | $82.99 | 2020-2025 | Sion Surgical Instrument, Omni Surgical System, Tearcare System |
| Oyster Point Pharma, INC. | $81.56 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $50.10 | 2019-2021 | |
| Dompe US, INC. | $48.67 | 2021-2024 | Oxervate |
| Thea Pharma INC. | $47.91 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.93 | 2020-2021 | |
| Shire North American Group INC | $44.74 | 2019 | |
| Optos, INC. | $42.25 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Amgen INC. | $39.35 | 2025 | Tepezza |
| Ocular Therapeutix, INC. | $38.52 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $33.17 | 2024-2025 | Xiidra, Miebo, Envista Envy Iol |
| Tarsus Pharmaceuticals, INC. | $31.84 | 2025 | Xdemvy |
| Tearlab Corp | $24.85 | 2023 | Tearlab Osmolarity System |
| Oasis Medical, INC. | $15.96 | 2022 | |
| Galderma Laboratories, L.P. | $13.55 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$209,083.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Parkhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.